Voyager Therapeutics, Inc. SEC filings VYGR
Voyager Therapeutics, Inc. has 681 filings in SEC EDGAR's recent list, going back to Apr 23, 2015. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 21, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 28, 2026 | Jun 9, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 10, 2026 | Jun 9, 2026 |
| DEFA14A | Additional proxy material | Apr 23, 2025 | — |
| DEF 14A | Proxy statement | Apr 23, 2025 | Jun 3, 2025 |
| DEFA14A | Additional proxy material | Apr 25, 2024 | — |
| DEF 14A | Proxy statement | Apr 25, 2024 | Jun 5, 2024 |
| DEFA14A | Additional proxy material | May 9, 2023 | — |
| DEFA14A | Additional proxy material | Apr 27, 2023 | — |
| DEF 14A | Proxy statement | Apr 27, 2023 | Jun 6, 2023 |
| DEFA14A | Additional proxy material | Apr 21, 2022 | — |
| DEF 14A | Proxy statement | Apr 21, 2022 | Jun 6, 2022 |
| DEFA14A | Additional proxy material | May 19, 2021 | — |
| DEF 14A | Proxy statement | Apr 22, 2021 | Jun 3, 2021 |
| DEF 14A | Proxy statement | Apr 22, 2020 | Jun 4, 2020 |
| DEF 14A | Proxy statement | Apr 23, 2019 | Jun 13, 2019 |
| DEF 14A | Proxy statement | Apr 27, 2018 | Jun 14, 2018 |
| DEF 14A | Proxy statement | Apr 25, 2017 | Jun 19, 2017 |
| DEF 14A | Proxy statement | Apr 22, 2016 | Jun 15, 2016 |
Showing 19 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- VYGR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Lexington, MA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1640266
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.